Home Metabolism PDE inhibitor Nerandomilast (BI 1015550)

research use only

Nerandomilast (BI 1015550) PDE4B Inhibitor

Cat.No.E1382

Nerandomilast (BI 1015550) is an orally active inhibitor of PDE4B with IC50 of 7.2 nM. It has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD).
Nerandomilast (BI 1015550) PDE inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 448.97

Jump to

Quality Control

Batch: E138201 DMSO]11 mg/mL]false]Ethanol]5 mg/mL]false]Water]Insoluble]false Purity: 99.54%
  • Cited in Nature Medicine for its top-tier quality
  • COA
  • NMR
  • HPLC
  • SDS
  • Datasheet
99.54

Solubility

In vitro
Batch:

DMSO : 11 mg/mL (24.5 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 448.97 Formula

C20H25ClN6O2S

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1423719-30-5 -- Storage of Stock Solutions

Mechanism of Action

Targets/IC50/Ki
PDE4B
7.2 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06241560 Not yet recruiting
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim
 August 6 2024 Phase 2
NCT06107036 Recruiting
Healthy
Boehringer Ingelheim
 March 4 2024 Phase 1
NCT05718648 Completed
Renal Insufficiency|Healthy
Boehringer Ingelheim
 February 9 2023 Phase 1
NCT04771286 Completed
Healthy
Boehringer Ingelheim
 March 25 2021 Phase 1
NCT03422068 Completed
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim
 March 16 2018 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map